Abstract 480P
Background
EGFR-mutant NSCLC patients(pts) have various types of co-mutation, such as TP53. Co-mutations contribute to high tumor heterogeneity in early NSCLC, potentially resulting in different clinical outcomes of resectable NSCLC. However, the impact of clinical benefit in pts with EGFR co-mutation in the ADAURA study remains unclear. Our study aimed to investigate the efficacy of the third-generation EGFR-TKI aumolertinib as adjuvant therapy for stage I-III EGFR-mutant NSCLC underwent R0 resection, and the impact of co-mutations on the clinical benefit.
Methods
We enrolled EGFR-mutant NSCLC pts who underwent radical surgery and received a daily dose of aumolertinib 110 mg. The duration of adjuvant therapy depended on the pts’pathologic stage and physical conditions. We evaluated the disease-free survival (DFS) and safety ,including the efficacy of aumolertinib in pts with co-mutation.
Results
This study retrospectively analyzed 91 cases of pathologically confirmed adenocarcinoma, EGFR positive mutation (19Del or L858R), and stage I-III NSCLC pts from August 2021 to August 2023. At the data cut-off, all pts have no symptoms of tumor recurrence. 62 pts (68.1%) have been followed up for ≥ 6 months, 27 pts (29.7%) have been followed up for ≥ 12 months. The 1-year DFS rate is 100%.
Among them, 35 pts had EGFR co-mutation and 48.5% was with TP53 co-mutation. Median age was 59 years and 74.3% were female. 17 pts (48.6%) have been followed up for ≥ 6 months, 7 pts (20%) have been followed up for ≥ 12 months. At 12 months, 100% pts were alive and disease-free, consistent with the overall population. There was no difference in postoperative recurrence between the co-mutation and the overall population currently. No grade≥3 adverse events occurred. The common adverse events were mild rash and diarrhea. No pts withdrew from therapy due to adverse drug reactions.
Conclusions
This study demonstrated the significant efficacy of aumolertinib as adjuvant therapy for completely resected stage I-III EGFR-mutated NSCLC, and reported the consistent efficacy of aumolertinib in pts with co-mutation for the first time. Our study is still ongoing to expand the cohort of pts with co-mutation and extend the follow-up period to determine longer-term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract